arrow
B

Bruce E. Johnson

Dana-Farber Cancer Institute
H指数:123
被引数:8.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Understanding tumor-immune-stromal dynamics driving response and resistance to immune checkpoint blockade in melanoma
2025-11-010
PRE
A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma

TP53相关的组织重塑细胞和空间图谱定义了肺腺癌中的多细胞肿瘤生态系统

2025-10-070
PRE
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study

一线免疫治疗联合或不联合化疗与BRAF联合MEK抑制剂在BRAFV600E突变型转移性非小细胞肺癌中的比较(FRONT-BRAF):一项多中心、回顾性队列研究

2025-09-290
PRE
Clinical Implementation of Matched Tumor/Germline Sequencing Improves Accuracy of Tumor Genomic Profiling and Therapeutic Recommendations

匹配的肿瘤/体细胞测序的临床实施提高了肿瘤基因组分析准确性及治疗建议的准确性

2025-07-220
PRE
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients

老年非小细胞肺癌患者(≥80岁)的肿瘤免疫表型相关性及PD-L1高表达(≥50%)患者接受一线帕博利珠单抗治疗的结局

2025-02-040
PRE
Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2

HER2-negative乳腺癌的分子表征揭示了一个具有17q12缺失和ERBB2杂合性缺失的独特患者亚组

2025-02-010
PRE
Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association With the Outcomes of Immunotherapy With or Without Chemotherapy in Nonsquamous NSCLC

STK11、KEAP1和SMARCA4基因拷贝数缺失:临床病理特征及其与免疫治疗联合或单独化疗在非鳞状NSCLC中疗效的关联

2025-01-270
PRE
A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors

一项关于ramucirumab和生长抑素类似物疗法在晚期神经内分泌肿瘤患者中的II期研究

2025-01-210
OA
Lung cancer research and treatment: global perspectives and strategic calls to action

肺癌研究与治疗: 全球视角与战略行动呼吁

2024-12-010
PRE
A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features

跨临床病理特征的转移性乳腺癌活检的多模态单细胞和空间表达图

2024-10-301
OAAI
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer

非小细胞肺癌患者PD-L1表达和肿瘤突变负荷的体内变化及其对免疫检查点抑制剂治疗结局的影响

2024-10-010
PRE
Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer (vol 15, 5837, 2024)

888儿科肿瘤的分子谱分析为未来的精确试验和儿科癌症的数据共享计划提供了信息 (第15卷,5837,2024)

2024-08-220
OAAI
Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer

888种儿科肿瘤的分子谱分析为未来儿科癌症的精确试验和数据共享计划提供了依据

2024-07-112
OAAI
Comprehensive clinicogenomic characterization of inflammatory breast cancer
2024-05-020
PRE
Characterization and proposed therapeutic exploitation of fusion RNAs in metastatic breast cancers
2024-05-021
PRE
Dissecting tumor- immune interaction in response and resistance to immune checkpoint blockade in metastatic melanoma
2024-03-220
PRE
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
2024-02-150
OAAI